Navigation Links
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
Date:6/10/2008

- Positive Phase II Results of Roche and Ipsen's First Once-Weekly Human

GLP-1 Presented at the American Diabetes Association Meeting -

NUTLEY, N.J., June 10 /PRNewswire/ -- Roche and Ipsen's investigational type 2 diabetes drug taspoglutide (R1583) has been shown to provide significant improvements in glucose control and weight loss after only eight weeks of treatment(1,2) with a safety and tolerability profile that supports entry into Phase III. Taspoglutide, originating from Ipsen's research, is the first human once weekly glucagon-like peptide-1 (GLP-1) analogue. It is a compound similar to the natural hormone GLP-1 which has a key role in blood sugar regulation. Based on these promising Phase II results presented at the American Diabetes Association (ADA) meeting in San Francisco, Roche has made the decision to move taspoglutide into Phase III clinical trials with the program anticipated to start in the second half of 2008.

"These data reinforce the role of GLP-1 in type 2 diabetes and Roche and Ipsen believe taspoglutide has the potential to be a best-in-class treatment," said William M. Burns, CEO, Pharmaceuticals Division of Roche and Jean-Luc Belingard, Chairman and CEO of the Ipsen Group. "GLP-1 analogues, which stimulate insulin secretion and suppress glucagon secretion, are true innovations in the diabetes field. Roche and Ipsen are pleased to move this potentially best-in-class product into phase III trials and look forward to working together to bring it to market," they said.

The Phase II studies showed that the safety profile of taspoglutide supports the move to Phase III with the most common adverse event reported being mild-to-moderate nausea. These events were dose-dependent, and in most cases, resolved spontaneously while continuing on therapy.

"These data show that taspoglutide is a promising once weekly treatment for patients with type 2 diabetes mellitus no longer controlled on oral antidiabetic medica
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
2. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
3. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
4. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Roche responds to announcement of IDEAL hepatitis C trial results
8. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
9. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
10. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
11. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
(Date:8/4/2015)... Aug. 4, 2015 BioElectronics Corporation (OTC ... Musculoskeletal Pain Therapy medical devices, announced today that ... ActiPatch 7-day trial device has been published in ... Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 ... submitted an assessment.  Chronic pain ...
(Date:8/4/2015)... DUBLIN , Aug. 4, 2015 Research ... of the "Alcohol Ethoxylate Market by Application (Household ... Geographies Global Market Trends, Forecasts to 2019" report ... of alcohol ethoxylate was valued at $5,124.9 million in ... of about 3.5% from 2014 to 2019. The data ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 2Global Alcohol Ethoxylate Market 2015 - Market Trends, Forecasts to 2019 for the $5.1 Billion Industry 3
... Regenerate Skeletal Muscle More,Efficiently than Male Cells, PITTSBURGH, April ... have a greater ability to regenerate skeletal,muscle tissue than ... Pittsburgh of UPMC. , The study, which is being ... Cell Biology, is the first ever to report a ...
... 10, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences Incorporated announced data ... pipeline, including its Hsp90,inhibitor, epothilone and nuclear export ... American Association for Cancer Research,(AACR), being held in ... on Kosan's programs are as follows. The,location for ...
Cached Medicine Technology:The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem,Cells Work Better 2The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem,Cells Work Better 3Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 2Kosan Announces Data Presentations at Upcoming AACR Annual Meeting 3
(Date:8/5/2015)... ... August 05, 2015 , ... ... Life CEO Ron Fugate invited employees to suggest ideas to add some fun ... of Marketing, had the winning idea to transform toilets into works of art. ...
(Date:8/5/2015)... , ... August 05, 2015 , ... Jvion’s CEO, ... by Becker’s Health IT & CIO Review. The designation is given to those leaders ... in driving the success of Jvion and the firm’s clinical predictive analytic solutions. , ...
(Date:8/5/2015)... ... August 05, 2015 , ... ... published updated guidelines for the management of malignant pleural mesothelioma. Details of the ... the article. , The updated guidelines issued by the European Society of ...
(Date:8/5/2015)... ... August 05, 2015 , ... What language does a body speak? ... “dictionary” of American idioms and other expressions that contain the name of a body ... This book contains about 2,000 such idioms, words, and expressions, for example, “back against ...
(Date:8/5/2015)... (PRWEB) , ... August 05, 2015 , ... Stelari introduces ... is reinventing yoga wear with their new line, The Earth’s Song. Combining fashion and ... and into your workout. Inspired by the Australian Outback, this collection is sure to ...
Breaking Medicine News(10 mins):Health News:Fantastic Team Spirit and Creativity Prevailed at Renew Life “Art de Toilettes” 2Health News:Jvion’s Shantanu Nigam Named One of the 21 Health IT Leaders to Know 2Health News:New Mesothelioma Treatment Guidelines Issued By European Researchers, According to Surviving Mesothelioma 2Health News:Harvard Medical Professor Dr. Per-Olof Hasselgren Pens Unique Book Using Body Part Idioms 2Health News:Stelari: Bohemian Chic Activewear Line 2Health News:Stelari: Bohemian Chic Activewear Line 3
... Rochelle, NY, March 4, 2009Overweight children and adolescents, with ... successfully lose weight by following the Seven Steps to ... Management , a journal published by Mary Ann ... www.liebertpub.com/obe , A team of experts ...
... another award for its Labmatrix(TM) platform being ... worldwide for translational research, biomarker discovery, biobanking, ... -- BioFortis, Inc., the leading ... pharmaceutical and institutional clients, today announced it ...
... Studies , ... Vienna (Vocus) March 5, 2009 -- ... PACS workstation at the European Congress of Radiology convention this ... for routine exams and 3D imaging studies where complex data sets ...
... AED industry-leading commitment to research and developmentGrand opening ... the American Academy of Dermatology (AAD)HAYWARD, Calif., March ... SLTM ) today announced the opening of the ... new product development, facilitate research on the innovative ...
... Over-the-Counter (OTC) Albolene(R) Moisturizing Cleanser as Effective as a Prescription ... N.J., March 5 Mild to moderate eczema sufferers who ... this skin condition without a prescription now have a new ... issue of the Journal of Cosmetic Dermatology (1) finds ...
... syndrome in strained unions, study finds , , THURSDAY, March 5 ... marriage may be greater for women than men, a new ... unions, those marked by arguing and being angry, were more ... the contentious relationships were more likely to develop high blood ...
Cached Medicine News:Health News:7 steps to successful child and adolescent weight loss 2Health News:BioFortis Wins Best Product Award in Discovery Informatics at the 2009 Molecular Medicine Tri-Conference 2Health News:Carestream Health Debuts Powerful New PACS Viewer As Work In Progress 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 3Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 2Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 3Health News:Bad Marriages Harder on Women's Health 2Health News:Bad Marriages Harder on Women's Health 3
... standard - the ones to compare with, the ... led in the development and standardization of immersion ... record: , When the FDA set general purpose ... Diagnostics in the 1970's, Cargille Immersion Oils were ...
... simple, easy and accurate one tube system ... and Shigella species. EnteroScreen 4™ is specifically ... and to aid in the detection and ... Three media, Modified Lysine Iron Agar, Lysine ...
... SpecTRACK Software is an Informatics software ... retrieval of specimens for the laboratory. With ... storage location of any specimen from all ... searches in the refrigerator or cold room. ...
... Proclear Multifocal are the only contact lenses ... by those with aging eyes: presbyopia and ... combine a superior lens design, Balanced Progressive ... using our patented PC Technology. The result? ...
Medicine Products: